Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 104.58B |
| Enterprise value | 94.17B |
| Trailing P/E | 29.13 |
| Forward P/E | 24.81 |
| PEG ratio (5-yr expected) | 0.54 |
| Price/sales (ttm) | 10.68 |
| Price/book (mrq) | 5.95 |
| Enterprise value/revenue | 9.54 |
| Enterprise value/EBITDA | 20.45 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.37 |
| 52-week change 3 | 25.24% |
| S&P500 52-week change 3 | 25.01% |
| 52-week high 3 | 448.40 |
| 52-week low 3 | 316.43 |
| 50-day moving average 3 | 412.89 |
| 200-day moving average 3 | 382.72 |
Share statistics
| Avg vol (3-month) 3 | 1.21M |
| Avg vol (10-day) 3 | 1.1M |
| Shares outstanding 5 | 258.46M |
| Implied shares outstanding 6 | 258.46M |
| Float 8 | 257.56M |
| % held by insiders 1 | 0.11% |
| % held by institutions 1 | 97.28% |
| Shares short (28 Mar 2024) 4 | 3.98M |
| Short ratio (28 Mar 2024) 4 | 3.84 |
| Short % of float (28 Mar 2024) 4 | 1.54% |
| Short % of shares outstanding (28 Mar 2024) 4 | 1.54% |
| Shares short (prior month 29 Feb 2024) 4 | 4.05M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 2:1 |
| Last split date 3 | 24 Aug 2000 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 36.68% |
| Operating margin (ttm) | 37.97% |
Management effectiveness
| Return on assets (ttm) | 13.17% |
| Return on equity (ttm) | 22.99% |
Income statement
| Revenue (ttm) | 9.87B |
| Revenue per share (ttm) | 38.30 |
| Quarterly revenue growth (yoy) | 9.30% |
| Gross profit (ttm) | N/A |
| EBITDA | 4.48B |
| Net income avi to common (ttm) | 3.62B |
| Diluted EPS (ttm) | 13.88 |
| Quarterly earnings growth (yoy) | 18.30% |
Balance sheet
| Total cash (mrq) | 11.22B |
| Total cash per share (mrq) | 43.43 |
| Total debt (mrq) | 808.4M |
| Total debt/equity (mrq) | 4.60% |
| Current ratio (mrq) | 3.99 |
| Book value per share (mrq) | 68.22 |
Cash flow statement
| Operating cash flow (ttm) | 3.54B |
| Levered free cash flow (ttm) | 3.51B |
© 2024 Yahoo. All rights reserved.